A Study of Tirzepatide (LY3298176) in Healthy Participants
Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
This study has three parts. Each participant will enroll in one part.
Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a
powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part
A will measure how much of the study drug gets into the blood stream and how long it takes
the body to get rid of it.
Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide
intravenous (IV) formulation when administered into a vein.
Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide
following multiple SC weekly doses of a solution.
This study will last approximately 70 days for Part A or Part B and 92 days for Part C. This
does not include screening. Screening is required within 28 days prior to the start of the
study.